Skip to main content

Table 1 Disease characteristics among patients who received radiotherapy during their treatment course (RT) and who didn’t (Non-RT), as well as in the whole population

From: Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses

  ALL patients
n (%)
Non-RT
n (%)
RT
n (%)
p
Age (years)     0.958
 Median 50 49 50  
 Range 21–75 28–75 21–68  
Sex     0.079
 Male 55 (59.1) 26 (51.0) 29 (69.0)  
 Female 38 (40.9) 25 (49.0) 13 (31.0)  
Histology     0.452
 Adenocarcinoma 90 (96.8) 50 (98.0) 40 (95.2)  
 Non-adenocarcinoma 3 (3.2) 1 (2.0) 2 (4.8)  
ECOG     0.814
 0–1 88 (94.6) 48 (94.1) 40 (95.2)  
 2 5 (5.4) 3 (5.9) 2 (4.8)  
Primary tumor Size (cm)     0.390
 Median 3.5 3.5 3.0  
 Range 0.0–8.0 0.0–8.0 0.0–7.9  
T stage     0.841
 T1–2 52 (55.9) 29 (56.9) 23 (54.8)  
 T3–4 41 (44.1) 22 (43.1) 19 (45.2)  
N stage     0.513
 N0 9 (9.7) 4 (7.8) 5 (11.9)  
 N1–3 84 (90.3) 47 (92.2) 37 (88.1)  
Number of metastatic organs     0.055
 1–2 66 (71.0) 32 (62.7) 34 (81.0)  
  ≥ 3 27 (29.0) 19 (37.3) 8 (19.0)  
Number of metastatic lesions     0.053
 1–5 28 (30.1) 11 (21.6) 17 (40.5)  
  ≥ 6 65 (69.9) 40 (78.4) 25 (59.5)  
Presence of lung metastases     0.069
 Yes 24 (25.8) 17 (33.3) 7 (16.7)  
 No 69 (74.2) 34 (67.7) 35 (83.3)  
Presence of liver metastases     0.119
 Yes 15 (16.1) 11 (21.6) 4 (9.5)  
 No 78 (83.9) 40 (78.4) 38 (90.5)  
Presence of brain metastases     0.010
 Yes 35 (37.6) 13 (25.5) 22 (52.4)  
 No 58 (62.4) 38 (74.5) 20 (47.6)  
Presence of adrenal metastases     0.086
 Yes 13 (14.0) 10 (19.6) 3 (7.1)  
 No 80 (86.0) 41 (80.4) 39 (92.9)  
Presence of Bone metastases     0.698
 Yes 33 (35.5) 19 (37.3) 14 (33.3)  
 No 60 (64.5) 32 (62.7) 28 (66.7)  
  1. ECOG Eastern Cooperative Oncology Group